» Articles » PMID: 3093966

Varicella: Complications and Costs

Overview
Journal Pediatrics
Specialty Pediatrics
Date 1986 Oct 1
PMID 3093966
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Varicella (chickenpox) has long been considered a benign, inevitable disease of childhood. Complications are generally mild and rarely severe, and virtually every individual is infected by adulthood. Infection is associated, however, with a high risk of serious complications in certain high-risk groups, such as leukemic children. Concerns about the severity of varicella in this population have led to the development and testing of a live, attenuated vaccine. Because of the favorable results thus far available, the vaccine may soon be licensed for use in high-risk individuals. The fact that a vaccine may soon be available has led to an increased interest in the potential benefits of a childhood varicella vaccine program. The costs associated with varicella infection in normal persons without a varicella vaccination program have been estimated to be approximately $400 million, 95% of which is the cost of caring for a child at home. Vaccination of normal 15-month-old children with a safe and effective vaccine with long-lasting immunity could reduce the cost by 66% and result in a savings of $7 for every dollar spent on the vaccination program. This assumes that vaccine would be administered only once with measles, mumps, and rubella vaccine, that there would be no increase in the number of varicella cases in older persons who are at increased risk for complications, and that there would be no deleterious effect on the occurrence and severity of herpes zoster.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Global Prevalence of Varicella-Associated Complications: A Systematic Review and Meta-Analysis.

Shah H, Meiwald A, Perera C, Casabona G, Richmond P, Jamet N Infect Dis Ther. 2023; 13(1):79-103.

PMID: 38117427 PMC: 10828225. DOI: 10.1007/s40121-023-00899-7.


Economic burden of varicella in Europe in the absence of universal varicella vaccination.

Pawaskar M, Meroc E, Samant S, Flem E, Bencina G, Riera-Montes M BMC Public Health. 2021; 21(1):2312.

PMID: 34930179 PMC: 8690977. DOI: 10.1186/s12889-021-12343-x.


The Cost-Effectiveness of Universal Varicella Vaccination in Italy: A Model-Based Assessment of Vaccination Strategies.

Azzari C, Baldo V, Giuffrida S, Gani R, OBrien E, Alimenti C Clinicoecon Outcomes Res. 2020; 12:273-283.

PMID: 32606844 PMC: 7294569. DOI: 10.2147/CEOR.S229685.


Implementation of Hospital Policy for Healthcare Workers and Patients Exposed to Varicella-Zoster Virus.

Kim S, Park S, Choi S, Lee D J Korean Med Sci. 2018; 33(36):e252.

PMID: 30181734 PMC: 6115693. DOI: 10.3346/jkms.2018.33.e252.


Modeling the impact of changes in day-care contact patterns on the dynamics of varicella transmission in France between 1991 and 2015.

Marziano V, Poletti P, Beraud G, Boelle P, Merler S, Colizza V PLoS Comput Biol. 2018; 14(8):e1006334.

PMID: 30067732 PMC: 6089450. DOI: 10.1371/journal.pcbi.1006334.